TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06547034

Intervention type: DEVICE
Intervention: Ultrasound
Description: Breast Ultrasound

Intervention type: DEVICE
Intervention: Ultrasound
Description: Breast Ultrasound
Study: NCT04103476

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
Description: Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04693689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RNA vaccine
Description: We elicit subjects' willingness to receive RNA COVID-19 vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RNA vaccine
Description: We elicit subjects' willingness to receive RNA COVID-19 vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RNA vaccine
Description: We elicit subjects' willingness to receive RNA COVID-19 vaccine
Study: NCT05918978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efgartigimod
Description: Participants will receive efgartigimod IV 10 mg/kg open label, respectively.
Study: NCT04693689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RNA vaccine
Description: We elicit subjects' willingness to receive RNA COVID-19 vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% adoption rate
Description: We elicit subjects' willingness to receive the new vaccine if 20% of the country's population has received it
Study: NCT06410144

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program A
Description: Subjects in the Control group will receive 1) National Kidney Foundation information, and 2) support from a kidney therapy educator.
Study: NCT04693689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20% adoption rate
Description: We elicit subjects' willingness to receive the new vaccine if 20% of the country's population has received it

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 40% adoption rate
Description: We elicit subjects' willingness to receive the new vaccine if 40% of the country's population has received it

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 40% adoption rate
Description: We elicit subjects' willingness to receive the new vaccine if 40% of the country's population has received it

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 60% adoption rate
Description: We elicit subjects' willingness to receive the new vaccine if 60% of the country's population has received it

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 60% adoption rate
Description: We elicit subjects' willingness to receive the new vaccine if 60% of the country's population has received it

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 80% adoption rate
Description: We elicit subjects' willingness to receive the new vaccine if 80% of the country's population has received it

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 80% adoption rate
Description: We elicit subjects' willingness to receive the new vaccine if 80% of the country's population has received it

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional vaccine
Description: We elicit subjects' willingness to receive conventional COVID-19 vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional vaccine
Description: We elicit subjects' willingness to receive conventional COVID-19 vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional vaccine
Description: We elicit subjects' willingness to receive conventional COVID-19 vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional vaccine
Description: We elicit subjects' willingness to receive conventional COVID-19 vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional vaccine
Description: We elicit subjects' willingness to receive conventional COVID-19 vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0% adoption rate
Description: We elicit subjects' willingness to receive the new vaccine if 0% of the country's population has received it

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0% adoption rate
Description: We elicit subjects' willingness to receive the new vaccine if 0% of the country's population has received it
Study: NCT06027073

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: omalizumab
Description: adding omalizumab to anti asthmatic therapy

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: omalizumab
Description: adding omalizumab to anti asthmatic therapy
Study: NCT06410144

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program B
Description: Subjects in the intervention group will receive 1) a video and paper decision aid, and 2) coaching from a palliative care clinician. The visits will be aimed at supporting patients with kidney therapy decision-making.
Study: NCT04619004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab Deruxtecan (Fixed dose)
Description: Patritumab deruxtecan will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab Deruxtecan (Up-Titration)
Description: Patritumab deruxtecan will be dosed as an intravenous (IV) infusion administered at Cycle 1, 3.2 mg/kg; Cycle 2, 4.8 mg/kg; Cycle 3 and subsequent cycles, 6.4 mg/kg administered on Day 1 of each 21-day cycle.
Study: NCT06414291

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plain Water
Description: Plain water without calories, sweetener, or electolytes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid IV Hydration Multiplier
Description: Drink with 22 grams of carbohydrate, 1020 milligrams of sodium, and 760 milligrams of potassium per liter. Hydration multiplier liquid IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid IV Sugar Free
Description: 10 grams of carbohydrate, 1060 milligrams of sodium, and 760 milligrams of potassium per liter. Sugar free Liquid IV
Study: NCT06483854

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV counseling and testing from a traditional health practitioner
Description: Healer provided HIV counseling and testing services offered to clients
Study: NCT06340230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 Injection + Adebrelimab Injection
Description: Drug: SHR-A1811 Injection Drug: Adebrelimab Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 Injection + Adebrelimab Injection
Description: Drug: SHR-A1811 Injection Drug: Adebrelimab Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 Injection
Description: Drug: SHR-A1811 Injection
Study: NCT06226051

Intervention type: DEVICE
Intervention: PEAPOD Infant Body Composition measuring device
Description: PEAPOD is a device to that collects body composition measurements.
Study: NCT06519682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: All patients will be administered Nivolumab with or without radiation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: All patients will be administered Nivolumab with or without radiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Radiation
Study: NCT05776524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125 mg/m2 weekly, on days 1,8, and 15 or on days 1 and 15 as a 30-40 minute infusion administered first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 weekly, on day 1,8 and 15 or 1000 mg/m2 weekly, on day 1 and 15 over 30 minutes after nab- paclitaxel infusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraBionic
Description: This treatment consists of delivering low levels of radio waves into the body with a spoon-shaped antenna placed in the mouth, three times a day, for an hour each time.
Study: NCT05791864

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-381
Description: One time subretinal dose in study eye

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-381
Description: One time subretinal dose in study eye

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-381
Description: One time subretinal dose in study eye

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-381
Description: One time subretinal dose in study eye

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RGX-381
Description: One time subretinal dose in study eye
Study: NCT04718909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib + sintilimab
Description: Regorafenib: 160 mg p.o. qd for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off).~Sintilimab: 200mg i.v. q3w.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: 160 mg p.o. qd for 3 weeks of every 4 week cycle.
Study: NCT06347575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of the caverStim device
Description: Implantation of caverStim in SCI patients.
Study: NCT05965141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aribulin;carboplatin;bevacizumab
Description: Aribulin combined with carboplatin and bevacizumab in first-line treatment of platinum-sensitive recurrent ovarian cancer.
Study: NCT05942092

Intervention type: PROCEDURE
Intervention: Breast conserving surgery
Description: Breast conserving surgery after lesion's localization with ROLL or magnetic seed

Intervention type: PROCEDURE
Intervention: Breast conserving surgery
Description: Breast conserving surgery after lesion's localization with ROLL or magnetic seed
Study: NCT04946487

Intervention type: PROCEDURE
Intervention: total laminectomy
Description: Total laminectomy removes the posterior ligamentous complex (PLC) at the fusion and superior levels.
Study: NCT05801367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formocresol
Description: Formocresol will be used as non-vital pulpotomy medicament (which is gold standard)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allium Sativum Oil
Description: Allium sativum oil will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)
Study: NCT04761016

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The current I-POP health model includes: 1) BSW HWC primary care medical home (for uninsured or Medicare patients), 2)BSW HWC providing diabetes prevention, nutrition education, weight loss, farm stands, physical activity programming (in collaboration with its onsite City of Dallas Park and Recreation Center), 3) BSW HWC programming at community sites in 75210, 4) Referrals to Parkland Hatcher Station clinic that provides health care to Medicaid patients, 5) Referrals between Parkland Hatcher Station and BSW HWC programming, 6) Community improvement in collaboration with Frazier Revitalization Inc. Individuals will have access to resources within our current, ongoing I-POP Health model, but without CHW navigation between BSW HWC and local service providers. Participants will complete follow-up visits for collection of study measures with study personnel at 6- and 10- months. At the end of the 10-month follow-up period, participants receive an assigned CHW and CHW-navigation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I-POP + CHW navigation
Description: Individuals randomized to this condition will be paired with a CHW to assist with navigation of I-POP Health resources at BSW HWC and entities in local zip codes. CHW navigation will occur through monthly one-on-one follow-up visits for a period of 10-months. Participants will complete study visits for collection of data measures at baseline, 6- and 10- month timepoints. Study participation ends with completion of 10-months data measures.
Study: NCT06027073

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: omalizumab
Description: adding omalizumab to anti asthmatic therapy
Study: NCT06392412

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fi-VR Cognitive Training
Description: All participants will 16 sessions over eight weeks, with two sessions per week, each lasting 70 minutes. Participants in the fi-VRCT will use the virtual reality system with head-mounted display and handheld controllers. The fi-VRCT will be administered by an experienced research assistant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Cognitive Training
Description: All participants will 16 sessions over eight weeks, with two sessions per week, each lasting 70 minutes. The CT control program will include cognitive board games designed to improve various cognitive capacities. Certified community occupational therapists will lead the CT control group.
Study: NCT06573008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GP681 40mg
Description: 2 x 20mg tablets taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GP681 Simulant
Description: Placebo tablets matching GP681 40mg
Study: NCT05476653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI procedure
Description: Pulmonary MRI based on a 1.5 T machine (Siemens VIDA) or a 3T machine (Siemens SOLA) without the use of contrast product according to a protocol based on a 3D-UTE sequence acquired in free breathing but with a respiratory synchronization system in association with weightings in T1 and T2.
Study: NCT06378437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLB-001
Description: Administered orally according to the assigned treatment schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLB-001
Description: Administered orally according to the assigned treatment schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLB-001
Description: Administered orally according to the assigned treatment schedule
Study: NCT06041295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: on-the-job training of lung expansion therapy
Description: on-the-job training of lung expansion therapy
Study: NCT05956587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B003
Description: Administration by intravenous infusion
Study: NCT06646952

Intervention type: DRUG
Intervention: 18F-FDG
Description: All study participants will undergo one 18F-FDG PET/ CT scan.
Study: NCT04805996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes remission using total diet replacement and eHealth contact with the healthcare provider
Description: Participants will replace usual foods with the commercially available total diet replacement Modifast (Impolin AB), which is delivered to them during the study period without any cost. Participants will be supplied with a scale, a finger-stick blood glucose meter and a blood pressure monitor and will be advised to measure body weight, fasting blood glucose and blood pressure every morning. The results are registered in the mobile phone application Telia Health Monitoring (Telia Sweden AB) and are wirelessly transmitted to the study team.
Study: NCT06172582

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 12-week lifestyle intervention
Description: A 12-week lifestyle intervention delivered via weekly group meetings in the House Chat Leaders (HCL's) homes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week lifestyle intervention
Description: A 12-week lifestyle intervention delivered via weekly group meetings in the House Chat Leaders (HCL's) homes
Study: NCT05200559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized monoclonal immunoglobulin (Ig) G4 antibody that inhibits lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response, allowing the immune system to target and destroy cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7777
Description: E7777 or denileukin diftitox is a recombinant cytotoxic fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met1-Thr387)-His and for human interleukin-2 (Ala1-Thr133), indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) whose malignant cells express the CD25 component of the IL-2 receptor.
Study: NCT05887791

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen hydrolysate
Description: Single dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen hydrolysate
Description: Single dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose
Study: NCT06237634

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: splint and exercise and advices
Description: A hand-wrist support splint and tendon shifting exercises were applied to the upper extremity of the affected side.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: splint and exercise and advices
Description: A hand-wrist support splint and tendon shifting exercises were applied to the upper extremity of the affected side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: splint and exercise and advices
Description: A hand-wrist support splint and tendon shifting exercises were applied to the upper extremity of the affected side.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Triamsinolon Asetonid ozone
Description: 40 mg (1 ml) of triamcinolone acetonide was injected to the median nerve's around at wrist level under ultrasound guidance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ozone
Description: In addition to the treatment and recommendations given to the first group, the affected side was injected with ultrasound-guided 3 cc ozone (O2-O3) into the wrist with a concentration of 10 micrograms/ml.
Study: NCT05715060

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Median sternotomy closure (sternal closure)
Description: Comparison of Sternal closure after cardiac surgery between conventional way which is by stainless steel wire \& Polydioxanone (PDS)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Median sternotomy closure (sternal closure)
Description: Comparison of Sternal closure after cardiac surgery between conventional way which is by stainless steel wire \& Polydioxanone (PDS)
Study: NCT05573139

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of muscle strength by manual dynamometry
Description: The reliability and validation of a new manual dynamometer was verified, compared to one already used, in the muscle groups: knee extensors and flexors; hip extensors, flexors, abductors, adductors, internal and external rotators.
Study: NCT05948189

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise program
Description: The participants of the intervention group received back health education (Back School) in the classroom. After the education program, they participated in exercise training for six weeks (one day a week).
Study: NCT05317598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kindness and honesty psychoeducation based on positive psychotherapy: The Key Model Of Courtesy And Integrity (KMCI)
Description: It is an application that investigates the effect of kindness and honesty psychoeducation based on positive psychotherapy on effective communication skills of nursing students.
Study: NCT05295628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMBLOK™ Embolic Protection System (EMBLOK EPS)
Description: The EMBLOK EPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SENTINEL™ Cerebral Protection System
Description: The SENTINEL CPS is intended to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures.
Study: NCT05899114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitional Multidisciplinary Pharmacotherapeutic Care
Description: A structured medication review with improved transitional care and multidisciplinary collaboration.~TMPC consists of the following four elements:~1. A structured pharmacotherapeutic analysis~2. A transitional multidisciplinary discussion.The treating physician in the hospital will be involved. The general practitioner and community pharmacist will be consulted.~3. An interview and discussion with the patient and/or legal representative by a member of the Pharmacotherapy-team, which will be performed before the patient is discharged from the hospital.~4. A discharge note with the pharmacotherapeutic care plan. This will be sent to the community pharmacist and the general practitioner.
Study: NCT06657365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) Treatment with Volnewmer
Description: Non-invasive radiofrequency-based skin tightening using the Volnewmer device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency (RF) Treatment with Thermage CPT
Description: Non-invasive radiofrequency-based skin tightening using the Thermage CPT device.